AMRYT PHARMA ORD 6P overview

Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Acromegaly patients were exposed to M ycapssa® during the g lobal Open - Label Extension ( OLE ) of the MPOWERED Phase 3 Trial for a maxim um of 3.5 years. - Patients switching from injectable Somatostatin Receptor Ligands (iSRLs) to M ycapssa® during the OLE...

Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6 , 2022 , Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“ Amryt ” or the “ Company ”) , a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases , today reminds shareholders of the key dates concerning the cancellation of the admission of its ordinary shares of nominal value £0.0 6 each (the “ Ordinary Shares ”)...

The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa ® (oral octreotide) in Acromegaly P atients DUBLIN, Ireland, and Boston MA, January 4 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that The Lancet Diabetes & Endocrinology has published the full results of the global Phase 3 MPOWERED...

Total Voting Rights DUBLIN, Ireland, and Boston M A, January 4 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on December 31, 2021 the issued share capital of the Company comprised 319,814,747 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of...

Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on November 30, 2021 the issued share capital of the Company comprised 319,657,247 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting...

Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018). Notification of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with them 1 Details of the person discharging managerial responsibilities/person closely associated a) Name Ray Stafford 2 Reason for the notification a)...

Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now expected in January 2022 DUBLIN, Ireland, and Boston MA, November 23 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the US Food and Drug Administration (“FDA”) has extended the review...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 (“UK MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A...